Published in Clin Cancer Res on July 01, 2008
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer (2010) 4.06
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle (2010) 1.48
Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol (2010) 1.44
Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol (2010) 1.39
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol (2012) 1.34
Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol (2010) 1.24
Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol (2013) 1.07
BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol (2014) 1.03
Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet (2012) 1.00
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS One (2011) 0.96
FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest (2013) 0.96
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol Cancer (2014) 0.93
NF-YA underlies EZH2 upregulation and is essential for proliferation of human epithelial ovarian cancer cells. Mol Cancer Res (2013) 0.93
Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis. PLoS One (2013) 0.92
Coevolution reveals a network of human proteins originating with multicellularity. Mol Biol Evol (2012) 0.88
Gene expression signature of normal cell-of-origin predicts ovarian tumor outcomes. PLoS One (2013) 0.87
In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. BMC Cell Biol (2013) 0.87
Tumor microenvironment-associated modifications of alternative splicing. RNA (2013) 0.85
The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer. Nucleic Acids Res (2015) 0.84
A Novel Subset of Human Tumors That Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate Cancers. Cancer Inform (2014) 0.81
Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma. Endocr Relat Cancer (2011) 0.81
Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications. Transl Cancer Res (2015) 0.80
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. BMC Cancer (2010) 0.80
Glucocorticoid-induced reversal of interleukin-1β-stimulated inflammatory gene expression in human oviductal cells. PLoS One (2014) 0.80
Salpingectomy as standard at hysterectomy? A Danish cohort study, 1977-2010. BMJ Open (2013) 0.79
Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. Neoplasia (2010) 0.79
Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prev Res (Phila) (2016) 0.76
Loss of LKB1 and p53 synergizes to alter fallopian tube epithelial phenotype and high-grade serous tumorigenesis. Oncogene (2015) 0.76
BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress. Cell Death Dis (2016) 0.76
The oviductal transcriptome is influenced by a local ovarian effect in the sow. J Ovarian Res (2016) 0.75
Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention. Front Oncol (2016) 0.75
Effect of menopause on hormonal receptors in ampullae of the fallopian tube with a special reference to the p53 signature. Int J Womens Health (2017) 0.75
BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
A conditional knockout resource for the genome-wide study of mouse gene function. Nature (2011) 9.93
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol (2005) 3.26
PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst (2013) 3.15
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
The mammalian gene function resource: the International Knockout Mouse Consortium. Mamm Genome (2012) 2.65
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ (2014) 2.60
GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology (2012) 2.48
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol (2011) 2.19
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer (2008) 2.13
Dual RMCE for efficient re-engineering of mouse mutant alleles. Nat Methods (2010) 2.05
Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol (2005) 1.98
Discovery of biomarkers of endometrial receptivity through a minimally invasive approach: a validation study with implications for assisted reproduction. Fertil Steril (2013) 1.98
Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol (2009) 1.91
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol (2007) 1.89
A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res (2007) 1.80
Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol (2006) 1.79
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 1.68
Knowledge of adverse drug reaction reporting in first year postgraduate doctors in a medical college. Ther Clin Risk Manag (2012) 1.65
Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol (2010) 1.64
The fallopian tube: primary site of most pelvic high-grade serous carcinomas. Int J Gynecol Cancer (2009) 1.60
Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol (2002) 1.59
Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer (2009) 1.57
Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer (2006) 1.53
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology (2004) 1.53
Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecol Oncol (2012) 1.49
Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst (2012) 1.48
Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT). Mol Biosyst (2008) 1.37
A scalable pipeline for highly effective genetic modification of a malaria parasite. Nat Methods (2011) 1.31
Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest (2011) 1.27
High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia (2005) 1.22
Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst (2010) 1.21
Exploiting alternative subcellular location for replication: tombusvirus replication switches to the endoplasmic reticulum in the absence of peroxisomes. Virology (2007) 1.20
Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study. Gynecol Oncol (2008) 1.19
Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration. BMC Cancer (2008) 1.17
Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev (2012) 1.17
The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol (2006) 1.14
Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol (2012) 1.13
A review on applicability of naturally available adsorbents for the removal of hazardous dyes from aqueous waste. Environ Monit Assess (2011) 1.08
Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res (2002) 1.04
Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. Int J Cancer (2011) 1.04
Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2. Cancer Epidemiol Biomarkers Prev (2006) 1.03
Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connect Tissue Res (2002) 1.03
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res (2006) 1.01
The optimum organization for the delivery of colposcopy service in Ontario: a systematic review. J Low Genit Tract Dis (2010) 0.99
The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol (2013) 0.98
Induction of nitric oxide release from the human alveolar epithelial cell line A549: an in vitro correlate of innate immune response to Mycobacterium tuberculosis. Immunology (2004) 0.97
Mycobacterium tuberculosis induces high production of nitric oxide in coordination with production of tumour necrosis factor-alpha in patients with fresh active tuberculosis but not in MDR tuberculosis. Immunol Cell Biol (2004) 0.96
Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Med (2007) 0.95
Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. Int J Radiat Oncol Biol Phys (2005) 0.94
A designed conformational shift to control protein binding specificity. Angew Chem Int Ed Engl (2014) 0.93
Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int J Cancer (2002) 0.93
Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol (2010) 0.92
Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinoma. Cancer (2003) 0.92
Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2011) 0.92
Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol (2005) 0.91
Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer. Neoplasia (2008) 0.91
Adenocarcinoma involving the uterine cervix: magnetic resonance imaging findings in tumours of endometrial, compared with cervical, origin. Can Assoc Radiol J (2006) 0.91
Proteome-wide overexpression of host proteins for identification of factors affecting tombusvirus RNA replication: an inhibitory role of protein kinase C. J Virol (2012) 0.90
Adipogenesis: new insights into brown adipose tissue differentiation. J Mol Endocrinol (2013) 0.90
Leydig cell tumor: an unusual presentation. Indian J Pathol Microbiol (2009) 0.90
Selectively filtering short wavelengths attenuates the disruptive effects of nocturnal light on endocrine and molecular circadian phase markers in rats. Endocrinology (2008) 0.89
Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status. Clin Cancer Res (2012) 0.89
Surgical outcome of robotic surgery in morbidly obese patient with endometrial cancer compared to laparotomy. Int J Gynecol Cancer (2012) 0.89
Height, weight, BMI and ovarian cancer survival. Gynecol Oncol (2012) 0.88
Characterization of Mce4A protein of Mycobacterium tuberculosis: role in invasion and survival. BMC Microbiol (2008) 0.88
Initial evaluation and referral guidelines for management of pelvic/ovarian masses. J Obstet Gynaecol Can (2009) 0.88
Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol (2014) 0.87
Teaching cervical cancer surgery in low- or middle-resource countries. Int J Gynecol Cancer (2010) 0.87
Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers. J Pathol (2011) 0.87
Flavonoids can block PSA production by breast and prostate cancer cell lines. Clin Chim Acta (2002) 0.86
Using the ICF in goal setting: clinical application using Talking Mats. Disabil Rehabil Assist Technol (2006) 0.86
Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis (2007) 0.86